|
gptkbp:instanceOf
|
antipsychotic medication
diphenylbutylpiperidine
|
|
gptkbp:approvedBy
|
1967
|
|
gptkbp:ATCCode
|
gptkb:N05AG02
|
|
gptkbp:brand
|
Orap
|
|
gptkbp:CASNumber
|
gptkb:2062-78-4
|
|
gptkbp:chemicalFormula
|
gptkb:C28H29F2N3O
|
|
gptkbp:contraindication
|
gptkb:congenital_long_QT_syndrome
gptkb:arrhythmia
use with CYP3A4 inhibitors
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:drugClass
|
neuroleptic
typical antipsychotic
|
|
gptkbp:eliminationHalfLife
|
55-66 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pimozide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:CYP1A2
gptkb:CYP2D6
gptkb:CYP3A4
liver
|
|
gptkbp:molecularWeight
|
461.55 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:riskFactor
|
gptkb:hyperprolactinemia
seizures
sudden cardiac death
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
QT prolongation
extrapyramidal symptoms
neuroleptic malignant syndrome
tardive dyskinesia
|
|
gptkbp:status
|
FDA approved
|
|
gptkbp:synonym
|
Orap
R 6238
|
|
gptkbp:usedFor
|
schizophrenia
Tourette syndrome
|
|
gptkbp:bfsParent
|
gptkb:Erythromycin
gptkb:Zoloft
|
|
gptkbp:bfsLayer
|
5
|